ROBERT KORMAN: Open Payments
NPI 1821030727 · NASHVILLE, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,799 in 68 payments from 16 companies in 2025. Trend: 2023 $256 · 2024 $1,185 · 2025 $1,799
Food & beverage: $1,799
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 11 | $441 |
| E.R. Squibb & Sons, L.L.C. | 11 | $260 |
| Alkermes, Inc. | 9 | $252 |
| Axsome Therapeutics, Inc. | 3 | $163 |
| Neurocrine BioSciences, Inc. | 5 | $137 |
| Corium, LLC | 8 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $72 |
| Bausch Health US, LLC | 4 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
Products named: FANAPT, COBENFY, Auvelity, INGREZZA, LYBALVI, HETLIOZ, ARISTADA, Azstarys.
Industry payments across TN — which companies pay providers there.
